Research programme: DprE1 inhibitor therapeutics - UniQuest

Drug Profile

Research programme: DprE1 inhibitor therapeutics - UniQuest

Alternative Names: BTZ043

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class Benzothiadiazines; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 04 Aug 2016 Research programme: DprE1 inhibitor therapeutics - UniQuest is available for licensing -https://www.nlm.nih.gov/cgi/mesh/2013/MB_cgi?mode=&index=245645&field=all&HM=&II=&PA=&form=&input=
  • 04 Aug 2016 Preclinical trials in Tuberculosis in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top